DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF

Abstract excerpt

MAPK inhibitors (MAPKi) remain an important component of the standard of care for metastatic melanoma. However, acquired resistance to these drugs limits their therapeutic benefit. Tumor cells can become refractory to MAPKi by reactivation of ERK. When this happens, tumors often become sensitive to drug withdrawal. This drug addiction phenotype results from the hyperactivation of the oncogenic pathway, a...

Topics

Join the communities discussing this publication.

• Autophagy in Disease and Therapy
• Endoplasmic Reticulum Stress and Disease
• Melanoma and MAPK Pathways